Analyst Tejas Savant of Morgan Stanley maintained a Hold rating on CryoPort (CYRX – Research Report), reducing the price target to $7.00.
Tejas Savant has given his Hold rating due to a combination of factors affecting CryoPort’s financial outlook. The recent divestiture of CRYOPDP has led to a significant adjustment in revenue estimates for the company, with projections for 2025 and 2026 being notably reduced. This adjustment reflects a more conservative outlook on the company’s future earnings potential.
Additionally, the price target for CryoPort’s stock is set at $7, based on a 1.6x EV/2025 Sales target multiple. This valuation is at a discount compared to peers in the cell and gene therapy market, which are trading at higher multiples. These factors together suggest a cautious approach, justifying the Hold rating as the company navigates through these changes.
In another report released on April 17, Leerink Partners also maintained a Hold rating on the stock with a $10.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYRX in relation to earlier this year.